drugset / Trial / NCT05218226
Avatrombopag for Chemotherapy-induced Thrombocytopenia
Phase 2
Unknown
50 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Henan Cancer Hospital · collabThe Second Affiliated Hospital of Kunming Medical University · collabTianjin Medical University Cancer Institute and Hospital · collabTianjin Medical University Second Hospital · collabTianjin People's Hospital · collabTianjin Third Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Avatrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
Timeline
- Start
- 2022-02-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 60 mg | — |